The IASLC recently announced that its main cancer journal, the Journal of Thoracic Oncology (JTO), improved its Impact Factor to 21.0 in 2023, up from 20.1 in 2022. The JTO, the official journal of the IASLC, now ranks second among 100 respiratory medicine journals and 13th among 322 oncology journals.
The JTO Clinical and Research Reports received its first Impact Factor of 3.0, ranking 142 out of 322 oncology journals and 37 out of 100 among respiratory journals. JTO Clinical and Research Reports (JTO CRR) is the official open-access journal of the IASLC.
Impact Factors are measured by calculating the number of times journal articles in the two preceding years are cited in a current year. Thus, the 2023 Impact Factor, which was released in June 2024, is calculated based on the number of times articles published in 2021 and 2022 are cited in 2023. The higher the Impact Factor, the more highly ranked the journal. Journal citation reports are issued by Clarivate Analytics.
The JTO is the primary educational publication for topics relevant to the prevention, detection, diagnosis, and treatment of thoracic malignancies. Emphasizing a multidisciplinary approach, the JTO includes original research, review articles, and opinion pieces.
“JTO’s impact factor for 2023 has risen to 21, making it only the second respiratory journal (after Lancet Respiratory Medicine) with an impact factor above 20,” said JTO Editor-in-Chief Alex A. Adjei, MD, PhD, FACP. “More importantly, it is the only thoracic oncology journal with an impact factor greater than 10. This is a notable achievement since we are a sub-specialty journal dealing with only thoracic oncology. There are no other sub-specialty journals among the top 20 oncology journals, and we now rank 13th out of 322 oncology journals. This achievement is a testament to the exemplary work of our editorial board and our editorial office, as well as the support of IASLC—its executives, office staff, membership, and above all, our reviewers, readers, and authors. JTO will continue its emphasis on multidisciplinary research to serve the broad community working in thoracic oncology.”
As the companion journal of the JTO, JTO CRR provides a publication hub within the IASLC for research with a more clinical focus and for article types such as case reports, phase 1 and 2 trials, high-impact retrospective studies, and database analyses. Being open-access, the journal offers immediate and permanently free access to quality lung cancer studies to everyone.
“The JTO CRR team is celebrating our first impact factor at 3.0, and we wish to thank everyone who made it possible—the authors, reviewers, editors, and the IASLC. We are thrilled to make such a terrific start, which truly reflects our commitment to excellence in science,” said JTO CRR Editor-in-Chief Emily Stone, MBBS, PhD, FRACP.
To submit a manuscript or to learn more about JTO, please visit jto.org. The complete contents of the JTO is free for IASLC members. Find JTO CRR at jtocrr.org.
